Magnetocardiography in the Accurate Identification of Severe Coronary Lesions and Myocardial Necrosis
Primary Purpose
Chest Pain, Acute Coronary Syndrome, Myocardial Infarction
Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Magnetometer
Sponsored by
About this trial
This is an interventional diagnostic trial for Chest Pain, Acute Coronary Syndrome, Myocardial Infarction
Eligibility Criteria
For healthy volunteers:
Inclusion Criteria:
- Age 18-79 years old;
- No history of cardiovascular disease (coronary heart disease, structural heart disease, arrhythmia, heart failure, stroke, pulmonary embolism, aortic dissection, etc.), no cardiovascular risk factors (hypertension, diabetes, hyperlipidemia). For people over 65 years old, those with hypertension or hyperlipidemia, but with well-controlled blood pressure and lipid levels, taking no more than 2 drugs, and echocardiography showing no left ventricular hypertrophy, can be included;
- The electrocardiogram is normal, and the cardiac ultrasound is basically normal in the past 1 year (mild valvular regurgitation can be included).
- Sign the informed consent.
Exclusion Criteria:
- Those who with acute or chronic respiratory diseases;
- Those who with obvious abnormality of liver or kidney function;
- Those who with endocrine diseases such as abnormal thyroid function;
- Those who with anemia or other blood diseases;
- Those who with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.);
- Those who are obese (BMI>30kg/cm2) or underweight (BMI<18kg/cm2);
- Those who with malignant tumors;
- Those who with infectious diseases or infectious diseases;
- Those who with trauma or physical disability;
- Those who with psychological or mental illness such as depression;
- Those who are professional athletes, pregnant or breastfeeding women, alcoholics;
- Those who are unable to perform magnetocardiography examination due to claustrophobia, etc., or those who fail to receive magnetocardiography examination;
- Due to various reasons such as allergy to contrast agents, metal implants in vivo that are prohibited from performing 1.5T MRI (such as prostheses or steel plates implanted in orthopaedics, uterine contraceptive device) and other reasons, those who cannot or fail to cooperate with the corresponding research requirements.
For chest pain patients who will undergo CAG or CTA:
Inclusion Criteria:
- Age 18-79 years old;
- Those with chest pain symptoms, diagnosed or highly suspected by the attending doctor or above as stable angina pectoris (SA), unstable angina pectoris (UA), non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevation myocardial infarction (STEMI), and plan to receive CAG or coronary CTA;
- Sign the informed consent.
Exclusion Criteria:
- Patients with known structural heart disease such as cardiomyopathy and valvular disease;
- Patients with arrhythmias such as atrial fibrillation, supraventricular tachycardia, and atrioventricular block that have not returned to normal;
- History of other cardiovascular diseases such as pulmonary embolism and aortic dissection;
- Patients with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.) combined with cardiac complications;
- Obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply;
- Obese (BMI>30kg/cm2) or underweight (BMI<18kg/cm2);
- Patients with malignant tumors;
- Professional athletes, pregnant or breastfeeding women, alcoholics;
- Acute diseases or critical illnesses in other systems, such as acute or severe respiratory diseases, abnormal liver function or renal function, etc.;
- Patients with infectious diseases or infectious diseases;
- Those who are unable or fail to perform magnetocardiography due to claustrophobia, physical impairment, etc.;
- Unable to or fail to cooperate with the corresponding research requirements.
For AMI patients:
Inclusion Criteria:
- Age 18-79 years old;
- The attending doctor or above has diagnosed the patient as acute myocardial infarction (NSTEMI, STEMI), the condition of whom is relatively stable, and CMR examination is feasible after evaluation.
- Sign the informed consent.
Exclusion Criteria:
- Patients with known structural heart disease such as cardiomyopathy and valvular disease;
- Patients with arrhythmias such as atrial fibrillation, supraventricular tachycardia, and atrioventricular block that have not returned to normal;
- History of other cardiovascular diseases such as pulmonary embolism and aortic dissection;
- Patients with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.) combined with cardiac complications;
- Obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply;
- Obese (BMI>30kg/cm2) or underweight (BMI<18kg/cm2);
- Patients with malignant tumors;
- Professional athletes, pregnant or breastfeeding women, alcoholics;
- Acute diseases or critical illnesses in other systems, such as acute or severe respiratory diseases, abnormal liver function or renal function, etc.;
- Patients with infectious diseases or infectious diseases;
- Those who are unable or fail to perform magnetocardiography due to claustrophobia, physical impairment, etc.;
- Due to various reasons such as allergy to contrast agents, metal implants in vivo that are prohibited from performing 1.5T MRI (such as prostheses or steel plates implanted in orthopaedics, uterine contraceptive device) and other reasons, those who cannot or fail to cooperate with the corresponding research requirements.
Sites / Locations
- Qilu Hospital of Shandong UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Other
Experimental
Experimental
Arm Label
healthy volunteers
Chest pain patients who will undergo CAG or CTA
AMI patients
Arm Description
Outcomes
Primary Outcome Measures
Accuracy of MCG to detect coronary lesion
To establish an algorithm model of MCG in detecting coronary lesion and to assess the sensitivity and specificity of the above model in detecting coronary lesion. Coronary lesion is measured by degree of stenosis via CAG/CTA and computer-simulated fraction flow reserve via QFR/CTFFR.
Accuracy of MCG to detect myocardial necrosis
To establish an algorithm model of MCG in detecting myocardial necrosis and to assess the sensitivity and specificity of this model in detecting myocardial necrosis, which is measured via cardiac MR.
Secondary Outcome Measures
Accuracy of MCG to detect the localization of coronary lesion
To build up an algorithm model of MCG in detecting the localization of coronary lesion. Assess the sensitivity and specificity of this model to detect the main vessels where the lesion locates.
Accuracy of MCG to detect the zone of myocardial necrosis
To establish an algorithm model of MCG to detect the infarct zone of the heart. Assess the sensitivity and specificity of this model to detect the location of myocardial necrosis.
Full Information
NCT ID
NCT05392712
First Posted
May 23, 2022
Last Updated
September 16, 2022
Sponsor
Qilu Hospital of Shandong University
Collaborators
Hangzhou Extremely Weak Magnetic Field Large Facility Research Institute
1. Study Identification
Unique Protocol Identification Number
NCT05392712
Brief Title
Magnetocardiography in the Accurate Identification of Severe Coronary Lesions and Myocardial Necrosis
Official Title
Ultra-sensitive Magnetocardiography in the Accurate Identification of Severe Coronary Lesions and Myocardial Necrosis
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 30, 2022 (Actual)
Primary Completion Date
December 2022 (Anticipated)
Study Completion Date
March 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Qilu Hospital of Shandong University
Collaborators
Hangzhou Extremely Weak Magnetic Field Large Facility Research Institute
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Magnetocardiography (MCG) is a promising noninvasive and accurate method for detecting myocardial ischemia. Although progress has been made in this area, there is a lack of studies using up-to-date examination instruments for the calibration of MCG analysis. This is a prospective single-center study aiming to build accurate analytical models of MCG to detect coronary lesions and myocardial necrosis. Coronary lesions are measured by coronary angiography (CAG) or coronary CTA, and are defined by both the stenosis degree and the computer-simulated fraction flow reserve. Myocardial necrosis is examined and quantified by cardiac MR. Healthy volunteers, chest pain patients who will receive CAG or CTA examination, and patients with acute myocardial infarction will be enrolled in this study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chest Pain, Acute Coronary Syndrome, Myocardial Infarction
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Outcomes Assessor
Allocation
Non-Randomized
Enrollment
430 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
healthy volunteers
Arm Type
Other
Arm Title
Chest pain patients who will undergo CAG or CTA
Arm Type
Experimental
Arm Title
AMI patients
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Magnetometer
Intervention Description
inspection equipment for magnetocardiography
Primary Outcome Measure Information:
Title
Accuracy of MCG to detect coronary lesion
Description
To establish an algorithm model of MCG in detecting coronary lesion and to assess the sensitivity and specificity of the above model in detecting coronary lesion. Coronary lesion is measured by degree of stenosis via CAG/CTA and computer-simulated fraction flow reserve via QFR/CTFFR.
Time Frame
24 hours
Title
Accuracy of MCG to detect myocardial necrosis
Description
To establish an algorithm model of MCG in detecting myocardial necrosis and to assess the sensitivity and specificity of this model in detecting myocardial necrosis, which is measured via cardiac MR.
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Accuracy of MCG to detect the localization of coronary lesion
Description
To build up an algorithm model of MCG in detecting the localization of coronary lesion. Assess the sensitivity and specificity of this model to detect the main vessels where the lesion locates.
Time Frame
24 hours
Title
Accuracy of MCG to detect the zone of myocardial necrosis
Description
To establish an algorithm model of MCG to detect the infarct zone of the heart. Assess the sensitivity and specificity of this model to detect the location of myocardial necrosis.
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
For healthy volunteers:
Inclusion Criteria:
Age 18-79 years old;
No history of cardiovascular disease (coronary heart disease, structural heart disease, arrhythmia, heart failure, stroke, pulmonary embolism, aortic dissection, etc.), no cardiovascular risk factors (hypertension, diabetes, hyperlipidemia). For people over 65 years old, those with hypertension or hyperlipidemia, but with well-controlled blood pressure and lipid levels, taking no more than 2 drugs, and echocardiography showing no left ventricular hypertrophy, can be included;
The electrocardiogram is normal, and the cardiac ultrasound is basically normal in the past 1 year (mild valvular regurgitation can be included).
Sign the informed consent.
Exclusion Criteria:
Those who with acute or chronic respiratory diseases;
Those who with obvious abnormality of liver or kidney function;
Those who with endocrine diseases such as abnormal thyroid function;
Those who with anemia or other blood diseases;
Those who with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.);
Those who are obese (BMI>30kg/cm2) or underweight (BMI<18kg/cm2);
Those who with malignant tumors;
Those who with infectious diseases or infectious diseases;
Those who with trauma or physical disability;
Those who with psychological or mental illness such as depression;
Those who are professional athletes, pregnant or breastfeeding women, alcoholics;
Those who are unable to perform magnetocardiography examination due to claustrophobia, etc., or those who fail to receive magnetocardiography examination;
Due to various reasons such as allergy to contrast agents, metal implants in vivo that are prohibited from performing 1.5T MRI (such as prostheses or steel plates implanted in orthopaedics, uterine contraceptive device) and other reasons, those who cannot or fail to cooperate with the corresponding research requirements.
For chest pain patients who will undergo CAG or CTA:
Inclusion Criteria:
Age 18-79 years old;
Those with chest pain symptoms, diagnosed or highly suspected by the attending doctor or above as stable angina pectoris (SA), unstable angina pectoris (UA), non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevation myocardial infarction (STEMI), and plan to receive CAG or coronary CTA;
Sign the informed consent.
Exclusion Criteria:
Patients with known structural heart disease such as cardiomyopathy and valvular disease;
Patients with arrhythmias such as atrial fibrillation, supraventricular tachycardia, and atrioventricular block that have not returned to normal;
History of other cardiovascular diseases such as pulmonary embolism and aortic dissection;
Patients with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.) combined with cardiac complications;
Obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply;
Obese (BMI>30kg/cm2) or underweight (BMI<18kg/cm2);
Patients with malignant tumors;
Professional athletes, pregnant or breastfeeding women, alcoholics;
Acute diseases or critical illnesses in other systems, such as acute or severe respiratory diseases, abnormal liver function or renal function, etc.;
Patients with infectious diseases or infectious diseases;
Those who are unable or fail to perform magnetocardiography due to claustrophobia, physical impairment, etc.;
Unable to or fail to cooperate with the corresponding research requirements.
For AMI patients:
Inclusion Criteria:
Age 18-79 years old;
The attending doctor or above has diagnosed the patient as acute myocardial infarction (NSTEMI, STEMI), the condition of whom is relatively stable, and CMR examination is feasible after evaluation.
Sign the informed consent.
Exclusion Criteria:
Patients with known structural heart disease such as cardiomyopathy and valvular disease;
Patients with arrhythmias such as atrial fibrillation, supraventricular tachycardia, and atrioventricular block that have not returned to normal;
History of other cardiovascular diseases such as pulmonary embolism and aortic dissection;
Patients with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.) combined with cardiac complications;
Obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply;
Obese (BMI>30kg/cm2) or underweight (BMI<18kg/cm2);
Patients with malignant tumors;
Professional athletes, pregnant or breastfeeding women, alcoholics;
Acute diseases or critical illnesses in other systems, such as acute or severe respiratory diseases, abnormal liver function or renal function, etc.;
Patients with infectious diseases or infectious diseases;
Those who are unable or fail to perform magnetocardiography due to claustrophobia, physical impairment, etc.;
Due to various reasons such as allergy to contrast agents, metal implants in vivo that are prohibited from performing 1.5T MRI (such as prostheses or steel plates implanted in orthopaedics, uterine contraceptive device) and other reasons, those who cannot or fail to cooperate with the corresponding research requirements.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jiaojiao Pang, Dr.
Phone
0086-0531-82165674
Email
jiaojiaopang@126.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yuguo Chen, Dr
Organizational Affiliation
Qilu Hospital of Shandong University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Qilu Hospital of Shandong University
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250012
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ping Li, Master
Phone
0086-0531-82160992
Email
liping0222@126.com
12. IPD Sharing Statement
Learn more about this trial
Magnetocardiography in the Accurate Identification of Severe Coronary Lesions and Myocardial Necrosis
We'll reach out to this number within 24 hrs